Biegelsen's Payment Policy Watch List For 2008
This article was originally published in The Gray Sheet
You may also be interested in...
Japan’s Device Payments Will Continue To Decline, Government Official Says
Pressures on reimbursement in Japan will not ease anytime soon and more payment cuts for medical devices are expected in 2008, according to a top Japanese health official
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.